Teva Pharmaceuticals (NYSE:TEVA) said today that it closed the $675 million cash sale of its Plan B One-Step product and emergency contraception assets to Foundation Consumer Healthcare. The move is part of Teva’s efforts to restructure its business, narrowing its focus on CNS and respiratory conditions. The company also plans to divest of its oncology and […]
Women's Health
Teva closes Paragard sale to CooperSurgical
Teva Pharmaceuticals (NYSE:TEVA) said today that it closed the $1.1 billion cash sale of its Paragard intrauterine copper contraceptive device to Cooper Cos.‘ (NYSE:COO) CooperSurgical unit. The deal included Teva’s manufacturing facility in Buffalo, N.Y., the pharma company reported. The move is part of Teva’s efforts to restructure its business, narrowing its focus on CNS and respiratory […]
Agile Therapeutics touts late-stage trial for once-weekly contraceptive patch
Agile Therapeutics (NSDQ:AGRX) touted data today from a Phase III trial of its once-weekly, low-dose hormonal contraceptive patch, Twirla. The study showed that women experienced mean decreases in length of bleeding and spotting episodes, the Princeton, N.J.-based company reported. Get the full story at our sister site, Drug Delivery Business News.
Artificial intelligence could prevent breast cancer false positives: Here’s how
Artificial intelligence could improve detection and diagnosis of breast cancer and eliminate false positives, according to new research out of the Massachusetts Institute of Technology’s Computer Science and Artificial Intelligence Laboratory (CSAIL). A team of researchers from MIT’s CSAIL, Massachusetts General Hospital and Harvard Medical School developed an AI system with machine learning that can […]
Viveve wins Mexican clearance for Viveve system
Viveve (NSDQ:VIVE) said today it won approval from Mexico’s regulatory authority, COFEPRIS, to market its Viveve system in Mexico with indications for treating vaginal introitus, after vaginal childbirth and to improve sexual function. The Englewood, Colo.-based company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus. The new regulatory clearance brings the […]
Bayer halts sales of Essure outside US
Bayer (ETR:BAYN) said today it is halting sales of its Essure contraceptive device outside the US in response to “commercial reasons” and not due to safety or product quality issues. The company said it originally announced it would pull the device from the shelves in most countries in May, and added that it will not resume […]
Teva sells off the rest of its women’s health assets in $2.5B deal
After the company divested its Paragard intrauterine device assets for $1.1 billion in cash last week, Teva Pharmaceuticals (NYSE:TEVA) announced today that it plans to sell off the rest of its global women’s health biz. Combined with proceeds from its Paragard deal, the sale of Teva’s global women’s health assets will total $2.48 billion, the company reported. Teva said […]
Endomag wins CE Mark for Magseed MIS breast cancer guide, inks 5-year distro deal
UK-based surgical guidance company Endomag said this week it won CE Mark approval in the European Union for its Magseed minimally invasive breast marker and that it inked a 5-year distribution deal with Sysmex. The company’s Magseed is designed to mark tumor sites with a ‘seed’, which it says is smaller than a grain of […]
Acessa Health touts data from 10-year review of uterine fibroid treatment
Acessa Health today touted data from a 10-year systematic review and meta-analysis of its Acessa system designed to treat uterine fibroids and comparable procedures, touting reduced blood loss, hospitalization time and readmission rates. Data from the 10-year review was presented at the MIS Week 2017 conference by Dr. Yelena Havryliuk of Weill Cornell Medical College. […]
GE Healthcare wins FDA nod for mammography system with patient controlled compression
GE Healthcare (NYSE:GE) said yesterday it won FDA 510(k) clearance for its Senographe Pristina Dueta, which it claims is the 1st patient-assisted mammography device that allows women to control their own compression during the examination. With the system, the woman undergoing the exam can control the application of compression on their breasts to minimize perceived pain […]
Enteris BioPharma launches endometriosis trial with oral peptide delivery tech
Enteris BioPharma, a 24-person biotech based in Boonton, N.J., last month launched a trial of its oral leuprolide endometriosis therapy, Ovarest. Ovarest is the company’s most advanced internal candidate and represents Enteris’ attempt to overcome the challenges presented by the oral delivery of peptides, according to CEO Joel Tune people can purchase peptides for sale […]